Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial-Reference-Cited by-同舟云学术

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Published:2020-04 Issue:10232 Volume:395 Page:1278-1291
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Sharman Jeff P,Egyed Miklos,Jurczak Wojciech,Skarbnik Alan,Pagel John M,Flinn Ian W,Kamdar Manali,Munir Talha,Walewska Renata,Corbett Gillian,Fogliatto Laura Maria,Herishanu Yair,Banerji Versha,Coutre Steven,Follows George,Walker Patricia,Karlsson Karin,Ghia Paolo,Janssens Ann,Cymbalista Florence,Woyach Jennifer A,Salles Gilles,Wierda William G,Izumi Raquel,Munugalavadla Veerendra,Patel Priti,Wang Min Hui,Wong Sofia,Byrd John C

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial;Eichhorst;Lancet Oncol,2016

2. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions;Fischer;N Engl J Med,2019

3. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial;Fischer;Blood,2016

4. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial;Hallek;Lancet,2010

5. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions;Goede;N Engl J Med,2014

Cited by 456 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial;Annals of Hematology;2024-09-14

2. Pharmacological management of chronic lymphocytic leukemia: current and emerging therapies;Expert Opinion on Pharmacotherapy;2024-09-08

3. Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia;Expert Review of Anticancer Therapy;2024-09-02

4. Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry;Clinical Lymphoma Myeloma and Leukemia;2024-09

5. Safety profile of first-line targeted therapies in elderly and/or comorbid chronic lymphocytic leukaemia patients (unfit subpopulation). A systematic review and network meta-analysis;Critical Reviews in Oncology/Hematology;2024-09